Nektar Therapeutics (NAS:NKTR)
$ 1.02 0.01 (0.99%) Market Cap: 186.30 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.74 GF Score: 56/100

Q2 2019 Nektar Therapeutics Earnings Call Transcript

Aug 08, 2019 / 09:00PM GMT
Release Date Price: $29.57 (+2.67%)
Operator

Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Q2 2019 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to introduce your host for today's conference, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.

Jennifer Ruddock
Nektar Therapeutics - SVP of Strategy & Corporate Affairs

Thank you, Crystal. Good afternoon, everyone, and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our Chief Financial Officer; Dr. Stephen Doberstein, our Head of R&D; Dr. Jonathan Zalevsky, our Chief Scientific Officer; and Dr. Mary Tagliaferri, our Chief Medical Officer.

On today's call, we expect to make forward-looking statements regarding our business, including clinical trial results, timing and plans for future clinical trials; timing and plans for future clinical data presentations at medical meetings; the therapeutic potential of our drug candidates; the effects of manufacturing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot